"Fluorouracil" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
Descriptor ID |
D005472
|
MeSH Number(s) |
D03.383.742.698.875.404
|
Concept/Terms |
Fluorouracil- Fluorouracil
- 5FU
- 5-FU
- 5-Fluorouracil
- 5 Fluorouracil
- Fluoruracil
Efudix- Efudix
- Fluoro-Uracile ICN
- Fluoro Uracile ICN
- Efudex
|
Below are MeSH descriptors whose meaning is more general than "Fluorouracil".
Below are MeSH descriptors whose meaning is more specific than "Fluorouracil".
This graph shows the total number of publications written about "Fluorouracil" by people in this website by year, and whether "Fluorouracil" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 9 | 11 |
1995 | 7 | 15 | 22 |
1996 | 3 | 7 | 10 |
1997 | 3 | 15 | 18 |
1998 | 4 | 24 | 28 |
1999 | 9 | 21 | 30 |
2000 | 4 | 20 | 24 |
2001 | 4 | 22 | 26 |
2002 | 3 | 14 | 17 |
2003 | 11 | 28 | 39 |
2004 | 11 | 31 | 42 |
2005 | 6 | 36 | 42 |
2006 | 5 | 44 | 49 |
2007 | 8 | 33 | 41 |
2008 | 6 | 24 | 30 |
2009 | 6 | 34 | 40 |
2010 | 6 | 25 | 31 |
2011 | 2 | 24 | 26 |
2012 | 1 | 21 | 22 |
2013 | 7 | 15 | 22 |
2014 | 3 | 25 | 28 |
2015 | 2 | 16 | 18 |
2016 | 4 | 15 | 19 |
2017 | 2 | 22 | 24 |
2018 | 1 | 9 | 10 |
2019 | 3 | 12 | 15 |
2020 | 4 | 20 | 24 |
2021 | 2 | 10 | 12 |
2022 | 0 | 11 | 11 |
2023 | 0 | 9 | 9 |
2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fluorouracil" by people in Profiles.
-
Impact of a non-therapeutic laparotomy in patients with locally advanced pancreatic cancer treated with induction (m)FOLFIRINOX: Trans-Atlantic Pancreatic Surgery (TAPS) Consortium study. Br J Surg. 2024 Mar 02; 111(3).
-
Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium Study. Ann Surg Oncol. 2024 Mar; 31(3):1919-1932.
-
Cell cycle arrest induces lipid droplet formation and confers ferroptosis resistance. Nat Commun. 2024 Jan 02; 15(1):79.
-
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2023 Dec; 24(12):1359-1374.
-
Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study. Signal Transduct Target Ther. 2023 09 27; 8(1):368.
-
Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023 Jul 27; 389(4):322-334.
-
Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048). J Clin Oncol. 2023 07 20; 41(21):3724-3734.
-
Long-term Outcomes of Bevacizumab and Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma: A Nonrandomized Controlled Trial. JAMA Netw Open. 2023 06 01; 6(6):e2316094.
-
Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial. JAMA Netw Open. 2023 06 01; 6(6):e2316161.
-
Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial. Cancer Med. 2023 06; 12(12):13352-13360.